Oramed Pharmaceuticals Inc. (ORMP) stock

ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30

$3.71−0.32 (-7.94%)

Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%

Oramed Pharmaceuticals EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Oramed Pharmaceuticals's EV/EBITDA was 187.1× on Sep 30, 2016, against 27.7× a year earlier.

Period	Period end	Value	Change (pts)
2016	Sep 30, 2016	187.1×	+167.0
2014	Sep 30, 2014	20.0×	−7.7
2013	Dec 31, 2013	27.7×	–

Parsed from the XBRL in Oramed Pharmaceuticals's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-12 reverse split on Jan 23, 2013
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ORMP.

Operating margin-810.1% · median -2093.7%

Net margin7244.3% · median -1351.3%

Advertisement
300 × 250

See a number that looks wrong?